Beta of Coherus BioSciences, Inc.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|NIHD NII Holdings, Inc.||NASDAQ > Public Utilities > Telecommunications Equipment||$474.3M|
|NTRA Natera, Inc.||NASDAQ > Health Care > Medical Specialities||$474.97M|
|WTBA West Bancorporation||NASDAQ > Finance > Major Banks||$475.27M|
|HCCI Heritage-Crystal Clean, Inc.||NASDAQ > Basic Industries > Miscellaneous||$476.82M|
|MNKD MannKind Corporation||NASDAQ > Health Care > Major Pharmaceuticals||$477.87M|
|BPT BP Prudhoe Bay Royalty Trust||NYSE > Energy > Integrated oil Companies||$478.35M|
|CHRS Coherus BioSciences, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||$478.51M|
|HDB HDFC Bank Limited||NYSE > Finance > Commercial Banks||$527.41B|
|MSFT Microsoft Corporation||NASDAQ > Technology > Computer Software: Prepackaged Software||$663.03B|
|GOOG Alphabet Inc.||NASDAQ > Technology > Computer Software: Programming, Data Processing||$663.31B|
|GOOGL Alphabet Inc.||NASDAQ > Technology > Computer Software: Programming, Data Processing||$663.8B|
|AMZN Amazon.com, Inc.||NASDAQ > Consumer Services > Catalog/Specialty Distribution||$714.48B|
|AAPL Apple Inc.||NASDAQ > Technology > Computer Manufacturing||$920.16B|